Equities research analysts expect Ritter Pharmaceuticals Inc (NASDAQ:RTTR) to announce earnings of ($1.09) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ritter Pharmaceuticals’ earnings. Ritter Pharmaceuticals reported earnings per share of ($1.10) during the same quarter last year, which indicates a positive year-over-year growth rate of 0.9%. The firm is scheduled to issue its next quarterly earnings results on Monday, March 18th.
According to Zacks, analysts expect that Ritter Pharmaceuticals will report full year earnings of ($3.05) per share for the current year. For the next financial year, analysts anticipate that the business will report earnings of ($1.20) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Ritter Pharmaceuticals.
Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.01.
A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. Vanguard Group Inc boosted its holdings in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) by 300.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,210 shares of the biotechnology company’s stock after acquiring an additional 42,180 shares during the period. Vanguard Group Inc owned about 0.98% of Ritter Pharmaceuticals worth $105,000 at the end of the most recent quarter. 12.55% of the stock is currently owned by institutional investors.
Shares of RTTR stock traded up $0.02 during trading hours on Tuesday, hitting $0.70. 641,400 shares of the company were exchanged, compared to its average volume of 221,514. Ritter Pharmaceuticals has a one year low of $0.47 and a one year high of $4.00. The stock has a market capitalization of $3.90 million, a price-to-earnings ratio of -0.14 and a beta of 1.45.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Read More: Why do companies engage in swaps?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.